KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study
In childhood leukemia, blood cancer burden after treatment matters more than genetic mutations for predicting survival.
In this large 11-center Chinese cohort of 289 pediatric CBF-AML patients, KIT and FLT3-ITD mutations did not independently predict survival outcomes, challenging their use as treatment escalation triggers in this setting. Post-induction MRD (flow cytometry and PCR) was the dominant prognostic factor, with implications for risk-adaptive treatment stratification.
What the study was
- Study design
- Retrospective multicenter cohort
- Population
- Pediatric CBF-AML (<14 years), newly diagnosed, C-HUANAN-AML-15 protocol 2015–2023; n=289 (11 centers)
- Sample size
- 289
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Annals of Hematology
Why it surfaced
Large multicenter pediatric AML cohort; directly relevant to clinical risk stratification; challenges widely used mutation-based escalation criteria; MRD-based stratification has immediate clinical implications.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.